Providing a VOICE for Missouri's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 2003
Meetings & Education
Financial Advocacy & Patient Assistance
State & Federal Resources
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
MOS Corporate Members
Become a Supporter
Industry News Archive
FDA Approves Pembrolizumab for Advanced Cervical Cancer
On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
Read the full FDA press release here.
Tweets by OSSatACCC